LIS1

About Xenothera

Xenothera is a clinical-stage biotech with a unique focus on engineering polyclonal antibodies. Its core technology, glyco-humanization (GH), removes non-human sugar antigens from antibodies derived from animals, aiming to create multispecific, low-immunogenicity therapies. The company has built an active pipeline targeting solid tumors, T-cell lymphomas, and infectious diseases, with its lead oncology candidate, XON7, already in clinical trials since 2023. Backed by a seasoned leadership team and strategic collaborations, Xenothera is positioning itself as an innovator in complex antibody therapeutics.

Therapeutic Areas